Adaptive Biotechnologies Corporation (ADPT)
ADPT trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/0001193125-26-076902-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ADPT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2019 |
| SEC CIK | 0001478320 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | WA |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $277.0M |
| Net income | -$59.5M |
| Operating income | -$57.1M |
| Net margin | -21.5% |
| Operating margin | -20.6% |
| Revenue growth | +54.8% |
| Cash | $70.5M |
| Total assets | $512.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 16.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $75.6M cash; operating cash flow -$1.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 161,876,694 (2026-10-30); 152,665,188 a year earlier; 144,772,751 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Seattle, Washington, United States | PCAOB Form AP 2026-03-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $117.6M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $83.9M | $2.9M | $9.6M | $75.6M | $0 | $298.0M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $71.6M | -$39.8M | -$6.4M | $169.9M | $0 | $308.1M | 10-Q 2026-08-04 |
| Q1 2026 2026-03-31 | $70.9M | -$20.0M | -$9.5M | $77.6M | $130.6M | $295.4M | 10-Q 2026-05-05 |
| Q4 2025 2025-12-31 | $71.7M | -$13.6M | $2.1M | $70.5M | $131.2M | $277.0M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $94.0M | $9.5M | -$7.1M | $55.0M | $131.8M | $252.8M | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $58.9M | -$25.6M | -$12.4M | $43.2M | $133.6M | $205.2M | 10-Q 2026-08-04 |
| Q1 2025 2025-03-31 | $52.4M | -$29.9M | -$28.5M | $50.6M | $133.6M | $189.5M | 10-Q 2026-05-05 |
| Q4 2024 2024-12-31 | $47.5M | -$33.7M | -$12.5M | $47.9M | $133.3M | $179.0M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B7 | 2020-08-21 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 839 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.8% |
| 1 month | +14.9% |
| 3 months | +18.7% |
| Year to date | +78.8% |
| 1 year | +105.4% |
| From 52-week high | -4.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CRSP | CRISPR Therapeutics AG Common Shares | $40.37 | -4.43% | $3.9B |
| TARS | Tarsus Pharmaceuticals Inc. | $78.68 | -1.99% | $3.9B |
| RLAY | Relay Therapeutics Inc. | $17.27 | -4.53% | $3.8B |
| SRRK | Scholar Rock Holding Corporation | $44.54 | +3.09% | $5.4B |
| IOVA | Iovance Biotherapeutics Inc. | $7.55 | -2.71% | $3.5B |
| IBRX | ImmunityBio Inc. | $5.98 | -0.66% | $6.4B |
| KOD | Kodiak Sciences Inc | $100.73 | -9.41% | $6.6B |
| ADMA | ADMA Biologics Inc | $13.47 | -1.54% | $3.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier